WallStSmart

Advanced Biomed Inc. Common Stock (ADVB)vsWaters Corporation (WAT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

WAT leads profitability with a 11.9% profit margin vs 0.0%. ADVB trades at a lower P/E of 1.1x. WAT earns a higher WallStSmart Score of 50/100 (C-).

ADVB

Hold

36

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 6.7Quality: 7.8
Piotroski: 4/9

WAT

Buy

50

out of 100

Grade: C-

Growth: 5.3Profit: 5.0Value: 3.3Quality: 7.0
Piotroski: 2/9Altman Z: 4.85
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ADVB.

WATSignificantly Overvalued (-84.6%)

Margin of Safety

-84.6%

Fair Value

$178.29

Current Price

$365.36

$187.07 premium

UndervaluedFair: $178.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ADVB3 strengths · Avg: 10.0/10
P/E RatioValuation
1.1x10/10

Attractively priced relative to earnings

Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

WAT2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
91.4%10/10

Revenue surging 91.4% year-over-year

Altman Z-ScoreHealth
4.8510/10

Safe zone — low bankruptcy risk

Areas to Watch

ADVB4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.18M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

WAT4 concerns · Avg: 3.5/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
2.9%3/10

ROE of 2.9% — below average capital efficiency

Operating MarginProfitability
2.8%3/10

Operating margin of 2.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : ADVB

The strongest argument for ADVB centers on P/E Ratio, Price/Book, Debt/Equity.

Bull Case : WAT

The strongest argument for WAT centers on Revenue Growth, Altman Z-Score. Revenue growth of 91.4% demonstrates continued momentum.

Bear Case : ADVB

The primary concerns for ADVB are Revenue Growth, EPS Growth, Market Cap.

Bear Case : WAT

The primary concerns for WAT are PEG Ratio, Price/Book, Return on Equity. A P/E of 45.2x leaves little room for execution misses.

Key Dynamics to Monitor

ADVB profiles as a value stock while WAT is a growth play — different risk/reward profiles.

WAT is growing revenue faster at 91.4% — sustainability is the question.

ADVB generates stronger free cash flow (-6,929), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

WAT scores higher overall (50/100 vs 36/100) and 91.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Advanced Biomed Inc. Common Stock

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. The company is headquartered in New York, New York.

Waters Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.

Want to dig deeper into these stocks?